DDR1-targeted therapies: current limitations and future potential

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Discoidin domain receptor (DDR)-1 plays a critical role in cellular processes like differentiation, proliferation, adhesion, migration, invasion, and extracellular matrix remodeling.
• Dysregulation of DDR1 is implicated in various pathologies, including cancer, fibrosis, atherosclerosis, and neurological disorders, positioning it as a significant therapeutic target.

Purpose of the Study:

• To review current therapeutic strategies targeting DDR1 from a medicinal chemistry standpoint.
• To analyze the reasons behind the limited success of DDR1 inhibitors, beyond known issues of selectivity and resistance.
• To highlight the need for further investigation into the complex interactions of DDR1 with the extracellular matrix and other signaling molecules.

Main Methods:

• Literature review of medicinal chemistry approaches for DDR1 inhibition.
• Analysis of factors contributing to the clinical efficacy of DDR1 inhibitors.
• Exploration of the interplay between DDR1, extracellular matrix, and other signaling pathways.

Main Results:

• Current therapeutic approaches targeting DDR1 are summarized from a medicinal chemistry perspective.
• Factors limiting the success of DDR1 inhibitors, including low selectivity and resistance, are discussed.
• The complex interactions of DDR1 with the extracellular matrix and other signaling molecules require further validation.

Conclusions:

• DDR1 is a promising therapeutic target for multiple diseases, but challenges in inhibitor development persist.
• Understanding the intricate DDR1-ECM interactions and its regulatory mechanisms in diseases like cancer and inflammation is crucial for advancing therapeutic strategies.